This dataset contains the results of screening 485 cancer cell lines with the Avana CRISPR-Cas9 genome-scale knockout library generated as part of the Broad Institute's Cancer Dependency Map project. It includes the results 49 lines not previously made public. <br><br>As our screening efforts continue, we will be releasing additional cancer dependency data on a quarterly basis for unrestricted use. For the latest datasets available, further analyses, and to subscribe to our mailing list visit https://depmap.org. <div><br>Descriptions of the experimental methods and the CERES algorithm are published in http://dx.doi.org/10.1038/ng.3984. Some cell lines were process using copy number data based on the Sanger Institute whole exome sequencing...
CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats – Cas9) is an innovative tech...
Cancer cell line genetic dependencies estimated using the DEMETER2 model. DEMETER2 is applied to thr...
SummaryOne approach to identifying cancer-specific vulnerabilities and therapeutic targets is to pro...
This dataset contains the results of screening 517 cancer cell lines with the Avana CRISPR-Cas9 geno...
This dataset contains the results of screening 558 cancer cell lines with the Avana CRISPR-Cas9 geno...
<div><div>Avana_public_18Q1 contains the results of screening 391 cancer cell lines with the Avana C...
This dataset contains the results of screening 43 cancer cell lines with the GeCKO CRISPR-Cas9 genom...
Cancer Dependency Map (DepMap) data used for analyses in the manuscript "WRN Helicase is a Synthetic...
These files provide the supplementary data supporting Dempster et al., "Agreement between two large ...
This DepMap release contains data from CRISPR knockout screens from project Achilles, as well as gen...
Pacini et al identify selective gene dependencies from CRISPR screens in 930 cell lines. Using clini...
Large panels of comprehensively characterized human cancer models, including the Cancer Cell Line En...
Read-count data for genome-scale CRISPR-Cas9 screens performed in MUG-Chor1 and UM-Chor1 chordoma ce...
One approach to identifying cancer-specific vulnerabilities and therapeutic targets is to profile ge...
Supplementary Table S8 showing the impact of removal of mutant KRAS in human cancer cell lines in vi...
CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats – Cas9) is an innovative tech...
Cancer cell line genetic dependencies estimated using the DEMETER2 model. DEMETER2 is applied to thr...
SummaryOne approach to identifying cancer-specific vulnerabilities and therapeutic targets is to pro...
This dataset contains the results of screening 517 cancer cell lines with the Avana CRISPR-Cas9 geno...
This dataset contains the results of screening 558 cancer cell lines with the Avana CRISPR-Cas9 geno...
<div><div>Avana_public_18Q1 contains the results of screening 391 cancer cell lines with the Avana C...
This dataset contains the results of screening 43 cancer cell lines with the GeCKO CRISPR-Cas9 genom...
Cancer Dependency Map (DepMap) data used for analyses in the manuscript "WRN Helicase is a Synthetic...
These files provide the supplementary data supporting Dempster et al., "Agreement between two large ...
This DepMap release contains data from CRISPR knockout screens from project Achilles, as well as gen...
Pacini et al identify selective gene dependencies from CRISPR screens in 930 cell lines. Using clini...
Large panels of comprehensively characterized human cancer models, including the Cancer Cell Line En...
Read-count data for genome-scale CRISPR-Cas9 screens performed in MUG-Chor1 and UM-Chor1 chordoma ce...
One approach to identifying cancer-specific vulnerabilities and therapeutic targets is to profile ge...
Supplementary Table S8 showing the impact of removal of mutant KRAS in human cancer cell lines in vi...
CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats – Cas9) is an innovative tech...
Cancer cell line genetic dependencies estimated using the DEMETER2 model. DEMETER2 is applied to thr...
SummaryOne approach to identifying cancer-specific vulnerabilities and therapeutic targets is to pro...